Singapore healthcare and biomedical companies are making a bigger play in overseas markets like the United States. Among them is biotech start-up Lucence, which developed a blood test to profile cancer. The liquid biopsy tests, which it started using in Singapore in 2018, is said to be much less invasive than conventional tissue biopsy and takes less time to administer and diagnose. The firm expanded to Silicon Valley three years ago. CNA’s Chloe Choo reports from New York City.
Subscribe to our channel here: [ Ссылка ]
Subscribe to our news service on Telegram: [ Ссылка ]
Follow us:
CNA: [ Ссылка ]
CNA Lifestyle: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
Twitter: [ Ссылка ]
TikTok: [ Ссылка ]
